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Reduced intracellular accumulation of drugs (due to rapid efflux) mediated by the efflux pump proteins belonging to ABC (ATP
Binding Cassette) andMFS (Major Facilitators) superfamily is one of the most common strategies adopted by multidrug resistance
(MDR) pathogenic yeasts. To combat MDR, it is essential to understand the structure and function of these transporters so that
inhibitors/modulators to these can be developed. The sequence alignments of the ABC transporters reveal selective divergence
within much conserved domains of Nucleotide-Binding Domains (NBDs) which is unique to all fungal transporters. Recently, the
role of conserved but divergent residues of Candida Drug Resistance 1 (CDR1), an ABC drug transporter of human pathogenic
Candida albicans, has been examined with regard to ATP binding and hydrolysis. In this paper, we focus on some of the recent
advances on the relevance of divergent and conserved amino acids of CaCdr1p and also discuss as to how drug interacts with Trans
Membrane Domains (TMDs) residues for its extrusion from MDR cells.
1. Introduction
The pathogenic Candida albicans accounts for approximately
50–60% causes of candidiasis particularly in immuno-
compromised human patients. But the infections caused
by non-albicans species, such as C. glabrata, C. parapsilosis,
C. tropicalis, and C. krusei are also common particularly in
neutropenic patients and neonates [1–4]. Of note, recently,
the incidences of albicans and non-albicans species of
Candida acquiring resistance to antifungals (particularly to
azoles) have increased considerably which poses problems
towards its successful chemotherapy [5–7]. On one hand,
to combat antifungal resistance, search for better drugs with
newer targets is underway; on the other hand, Candida cells
have evolved a variety of strategies to develop resistance to
common antifungals.
The main mechanisms of antifungal resistance to azoles
include alterations in ergosterol biosynthetic pathway by
an overexpression of ERG11 gene which encodes the drug
target enzyme 14∝-demethylase or by an alteration in
target enzymes (point mutations) [3, 8, 9]. Reduced intra-
cellular accumulation of drugs (due to rapid efflux) is
another prominent mechanism of resistance in Candida cells
[10]. Most commonly, genes encoding drug efflux pumps
belonging to ABC (ATP binding cassette) and MFS (Major
Facilitator) superfamilies of proteins are overexpressed in
azole resistant Candida isolates which abrogates intracellular
accumulation leading to enhanced tolerance to drugs (Fig-
ures 1(a) and 1(b)).
2. Efflux Pumps
Since ABC and MFS transporters are among the major
players that contribute to azole resistance in clinical isolates
of Candida, there is a spurt in research on all aspects of
these genes and their encoded proteins [6, 7]. In this context,
considerable attention is being paid to the structural and
functional aspects of these proteins, which in turn could
lead to better strategies for designing modulators/inhibitors
of these pumps. The genome of C. albicans possesses 28
ABC and 95 MFS proteins; however, only ABC transporters
CaCdr1p and CaCdr2p and MFS transporter CaMdr1p are
known to be multidrug transporters which play major role
in drug extrusion from resistant strains. In this review, we
2 Journal of Amino Acids
Out
In
NH2
COOHNBD
ATP ADP + Pi
NBD
ATP ADP + Pi
ATP
ABC
Drug
ADP + Pi
(a)
Out
In
COOH
NH2
H+
Drug
MFS
(b)
Figure 1: A cartoon representation of (a) ABC and (b) MFS transporters of Candida. The topology of ABC and the MFS transporters
depicted here have the (NBD-TMS6)2 and the (TMS)12 (Transmembrane Segments) arrangements, respectively. The NBDs (Nucleotide-
Binding Domains) of the ABC transporters are responsible for the hydrolysis of ATP, which facilitates drug extrusion while the MFS
transporters utilize proton gradient to expel drugs.
begin with a discussion on the structure and function of
ABC proteins and then focus on the role of some of the
critical amino acid residues of CaCdr1p in drug transport.
For brevity, we have excluded MFS drug transporters from
our discussion.
3. Structure and Function of
ABC Efflux Proteins
ABC proteins are generally made up of two transmembrane
domains (TMDs), each consisting of six transmembrane
segments (TMS) and two cytoplasmically located nucleotide-
binding domains (NBDs) which precedes each TMD (Fig-
ures 1(a) and 1(b)), [11, 12]. While it appears that several
TMSs associate together to form the substrate binding
site(s), this alone is probably not sufficient for substrate
transport across the membrane bilayer. Vectorial transport
of these substrates requires energy from the hydrolysis of
ATP carried out at the NBDs. Given their varied roles
and the greatly differing characteristics of substrates that
members of this superfamily of proteins seem to efflux, it
is hardly surprising that despite the overall conservation of
the domain architecture of TMDs, their primary sequences
are significantly different (Figure 2). On the other hand,
NBDs of ABC transporters which power drug transport are
highly conserved both in terms of primary structure and
architecture (Figure 3).
4. Candida Drug Resistance 1 (CDR1)
CDR1 of C. albicans, the first ABC efflux pump characterized
in any known pathogenic yeast, was isolated as a gene
implicated in conferring resistance to cycloheximide in
a PDR5 disruptant hypersensitive strain of S. cerevisiae
[13]. CaCDR1 codes for a protein of 1501 amino acid
residues (169.9 kDa), with a topology similar to that of
ABC proteins Pdr5p and Snq2p of S. cerevisiae. On the
other hand, its topology mirrors that of STE6, a -mating
pheromone transporter of S. cerevisiae, as well as of the
human MDR1 and CFTR. Despite a high structural and
functional similarity between CaCdr1p and ScPdr5p, some
distinct functional features tend to distinguish them. For
example, both genes share overlapping specificities for
cycloheximide and chloramphenicol but CaCDR1 affects
sensitivity to oligomycin while neither amplification nor
disruption of ScPDR5 alters susceptibilities to this mitochon-
drial inhibitor [13]. It is worth mentioning that some of
the close homologues of CaCDR1 in C. albicans are also
functionally distinct. For example, CaCdr2p that exhibits
84% identity with CaCdr1p has a distinct drug resistance
profile [14]. The overexpression or deletion of CaCDR3
and CaCDR4, the homologues of CaCDR1 and CaCDR2
interestingly do not affect drug susceptibilities of yeast cells
[15]. The hydropathy plots of CaCdr1p and CaCdr3p show
that both the proteins have similar topological arrangements
where the hydrophilic domain containing the NBDs precedes
the hydrophobic TMS [16]. The only apparent difference
between the two proteins appears to be in the C-terminal
where CaCdr3p has an extended loop connecting TM11 and
TM12. In addition, there is stretch of 21 amino acids in
the C-terminal of CaCdr3p which are absent in CaCdr1p
[16]. Keeping in view, the importance of these regions in
drug binding and transport, the subtle differences in the
primary structures of these proteins could be responsible
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Figure 2: Sequence logos of CaCdr1p transmembrane segment (TMSs) residues with other fungal PDR transporters. Each logo consists of
stacks of symbols, one stack for each position in the sequence. The scale indicates the certainty of finding a particular amino acid at a given
position and is determined by multiplying the frequency of that amino acid by the total information at that position. The residues at each
position are arranged in order of predominance from top to bottom, with the highest frequency residue at the top. The height of symbols
within the stack indicates the relative frequency of each amino acid at that position. Colors such as green defines polar, blue correspond to
basic, red to acidic, black to hydrophobic, and violet represent the amino acids that have polar amide group.
in governing their substrate specificity, hence only enabling
some of them (CaCdr1p and CaCdr2p) to bind and transport
drugs [17, 18].
To study the MDR proteins, a heterologous hyperexpres-
sion system is used where GFP tagged CaCdr1p/CaMdr1p
has been stably overexpressed from a genomic PDR5 locus
in a S. cerevisiae mutant AD1-8u− [19]. The host AD1-
8u− developed by Goffeau’s group [20] was derived from
a Pdr1-3 mutant strain with a gain of function mutation
in the transcription factor Pdr1p, resulting in constitutive
hyperinduction of the PDR5 promoter [19]. In previous
studies, we have confirmed that GFP tagging of CaCdr1p
(CaCDR1-GFP) and CaMdr1p (CaMDR1-GFP) did not
impair its expression and the functional activity of the
proteins [21, 22]. Figure 4 summarizes the strategy used for
the expression of CaCDR1-GFP under ScPDR5 promoter.
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Figure 3: Sequence alignment of the conserved motifs from fungal ABC transporters. Comparison of the sequence alignment of the walker
A, Q-loop, signature C, Walker B, and H-loop motifs of N- and C-terminal NBDs (NBD1 and NBD2) of CaCdr1p with known (a) fungal
and (b) nonfungal ABC transporters. Conserved but unique residues are highlighted.
5. How Does CaCDR1 Power Drug Efflux?
The characteristic feature of CaCdr1p or of any other ABC
drug transporter is that they utilize the energy of ATP
hydrolysis to transport variety of substrates across the plasma
membrane. The conserved NBDs located at the cytoplasmic
periphery are the hub of such an activity. The NBDs of all
ABC transporters, irrespective of their origin and nature
of transport substrate, share extensive amino acid sequence
identity within typical motifs [12]. For example, NBDs of
ABC transporters have a β-sheet subdomain containing the
typical Walker A and Walker B motifs, as an essential feature
of all ATP requiring enzymes [23], along with an α-helical
sub-domain that possesses the conserved ABC signature
sequence. NBD domain sequences possess certain conserved
amino acid stretches, which are considered to be critical
for its functionality [24]. These include: the Walker A, with
a consensus sequence GxxGxGKS/T, where “x” represents
any amino acid, the Walker B motif, that is, hhhhD, where
“h” represents any aliphatic residue, and an ABC signature,
LSGGQQ/R/KQR. Structural and biochemical analyses of
NBDs show that the well-conserved lysine residue of Walker
A motif binds to the β- and γ-phosphates of ribonucleotides
and plays a critical role in ATP hydrolysis [24]. Mutations
of this lysine residue have been shown to reduce or abolish
the hydrolysis activity and in some cases impair nucleotide
binding [24]. Interestingly, though N-terminal NBD of
CaCdr1p contains the conserved Walker A (GRPGAGCST)
and B (IQCWD) motifs, and an ABC signature sequence
(VSGGERKRVSIA) [25], the commonly occurring lysine
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Figure 4: Overexpression of CaCdr1p in a heterologous system. (a) Strategy showing the cloning and transformation of CaCDR1-GFP in S.
cerevisiae. (b) Pictorial representation of the host AD1-8u− showing the Deleted ABC pump proteins (pdr5, pdr10, pdr11, pdr15, snq2, yor1,
ycf1) and the hyper expressed CaCDR1-GFP. (c) Topology of CaCdr1p. (d) Localization of CaCdr1-GFP in the host strain AD1-8u−. The
rimmed green fluorescent depicts overexpressing GFP tagged CaCdr1p.
residue within the Walker A motif is replaced with a cysteine.
This replacement appears to be a unique feature of N-
terminal NBDs (N-NBD) of most of the known fungal ABC-
type transporters. In addition, degeneracy in Q loop and
Walker B also exist in N-NBDs of all fungal transporters
including in CaCdr1p. Notably, the C-terminal NBDs display
degeneracy only in signature motifs (discussed later).
To ascertain the role of the uncommon cysteine of
Walker A, active N-NBD of CaCdr1p was cloned and
overexpressed and the soluble domain protein was purified
and characterized. It was observed that an evolutionarily
divergent Cys193 of Walker A of N-NBD was critical for ATP
hydrolysis. The relative contribution of both the N- and C-
terminal NBDs in ATP binding, hydrolysis, and transporter
activity of native CaCdr1p (full protein) was examined
wherein the atypical Cys193 of Walker A of N-NBD (C193K)
and conserved Lys901 (K901C) in theWalker A of C-terminal
NBD (C-NBD) were replaced [26]. The drug resistance
profile of CaCdr1p mutant variant cells harboring C193K
or K901C gave interesting insights into the functioning
of the two NBDs. The cells expressing K901C showed
enhanced hypersensitivity to drugs as compared to C193K
variant which displayed partial sensitivity to select drugs.
These observations clearly established that the two NBDs
respond asymmetrically to the substitution of conserved
residues of their respective Walker A motifs. The functional
asymmetry of NBDs in CaCdr1p was also illustrated in
another study where swapping of NBDs resulted in non-
functional CaCdr1p chimeras and thus suggested that the
two NBDs are not identical and nonexchangeable [27].
Interestingly, in the case of human P-gp, a close homologue
of CaCdr1p, the issue of functional symmetry of two NBDs
remains contentious. Approaches addressing this issue in P-
gp provide data both in favor [28, 29] and against [30–
32] functional asymmetry. This is in contrast with many
other ABC transporters, for which there is evidence that the
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Figure 5: A hypothetical model depicting the N-terminal active site of CaCdr1p. The role of various residues involved in the catalytic
mechanism for ATP hydrolysis by the N-NBD of CaCdr1p the details are discussed in the text.
two NBDs, although highly similar in sequence, may adopt
different functional roles in the transport cycle [33].
Any functional asymmetry observed in the intact trans-
porter is probably not entirely due to inherent properties
of the NBD, and presumably also reflects either differences
in the rate of hydrolysis or the effects of interdomain inter-
actions. Two other residues of the N-NBD from CaCdr1p
are also found to be important for domain functioning.
As depicted in Figure 5, the unusual Trp326 in the Walker
B motif of N-NBD, which is unique and conserved in all
fungal transporters, is important for ATP binding and for the
accompanying conformational change [34]. Thus, although
the mutant with W326A appears capable of ATP hydrolysis,
it does so with a much higher KM value, indicating that
the docking of the substrate in the binding pocket has
been altered by the mutation. However, the protein appears
capable of near-normal function in cells expressing the
full-length protein carrying W326A mutation, implying
that the conformational change that normally occurs upon
ATP docking cannot by itself be responsible for the cross-
talk by the domain with the TMDs. While the highly
conserved Asp327 of N-NBD is shown to be the catalytic
carboxylate in the context of other ABC transporters, in N-
NBD of CaCdr1p, it does not appear to mediate catalysis
via interaction with Mg2+ as is normally expected for
similar transporters [34]. It has been shown that due to
spatial proximity, fluorescence resonance energy transfer
(FRET) takes place between Trp326 of Walker B and MIANS
[2-(4-maleimidoanilino) naphthalene-6-sulfonic acid] on
Cys193 of Walker A motif. These critical amino acids are
positioned within the nucleotide-binding pocket of N-NBD
to bind and hydrolyze ATP. The results show that both
Mg2+ coordination and nucleotide binding contribute to the
formation of the active site. The entry of Mg2+ into the
active site causes the first large conformational change that
brings Trp326 and Cys193 in close proximity to each other.
It was also demonstrated that besides Trp326, typical Glu238
in the Q-loop also participates in coordination of Mg2+ by
N-NBD. A second conformational change is induced when
ATP, but not ADP, docks into the pocket. The unique Asn328
does sensing of the γ-phosphate of the substrate in the
extended Walker B motif, which is essential for the second
conformational change that must necessarily precede ATP
hydrolysis.
It has been possible to deduce a picture of the catalytic
mechanism for ATP hydrolysis by the N-NBD of CaCdr1p
(Figure 5). The metal ion approaches the nucleotide binding
pocket and forms a π-stacking interaction with the delo-
calized electron cloud of Trp326 in Walker B. This induces
a large conformational change in the protein, bringing
Cys193, Glu238, Trp326, Asp327, and Asn328 closer into
the nucleotide binding pocket. At this point, the metal ion
is sufficiently far from the MIANS on Cys193 to have no
effect on its fluorescence intensity. However, Trp326 and
MIANS on Cys193 are within 16 A˚ of each other at this
point. ATP approaches with its phosphates directed towards
the pocket. As in other ATPases, it may be assumed that
the β and γ-phosphates also coordinately bind the metal
ion and their negative charges are considerably masked. This
is important since in the absence of the metal ion, the
nucleotide does not dock into the active site. While other
residues may also be involved in stabilizing the nucleotide
within the pocket, Asn328 certainly acts as a sensor for the γ-
phosphate. This induces the second conformational change
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Figure 6: Topology of CaCdr1p and sequence alignment of signature motifs from various ABC transporters. The sequence alignment of
signature motif residues in NBDs with those from other nucleotide-binding domains of some known ABC transporters is shown.
within the protein. Asp327 which acts as a catalytic base
abstracts a proton from a water molecule, that is, part of
the Mg-ATP complex present in the active site. The hydroxyl
ion, thus, formed in turn attacks at the β-phosphate allowing
it to, in turn, abstract a proton from the –SH of Cys193.
The consequence of this is to simultaneously weaken the
phosphodiester bond between β- and γ-phosphates, allowing
the latter to leave. Once ATP is hydrolyzed, Asn328 no longer
senses the γ-phosphate, and the conformation relaxes back
to a more open one allowing ADP to leave (Figure 5).
The data thus far unequivocally show that the N-NBD of
CaCdr1p and by extension those of other fungal transporters
have evolved so as to use their unique substitutions to
perform the task of ATP binding and hydrolysis. While it
is not yet clear what evolutionary advantage these typical
sequence variations might provide to the organisms, it is
becoming more and more evident that it has mechanistic
implications for the protein. We are yet to understand
how the N-NBD works in conjunction with the C-NBD to
give rise to a functional drug transporter. Does working in
tandem require the ABC Signature sequence of one NBD to
participate in ATP binding by the other, as is seen in other
ABC transporters? Like in the N-NBDs, the ABC signature
sequences of CaCdr1p and other fungal transporters too
appear to have diverged away from that of other ABC
transporters. Whether this is so as to compensate for the
substitutions in their N-NBDs or whether they have evolved a
new mechanism for coming together for ATP hydrolysis and
drug efflux is a question worth examining.
Signature motifs are other domains which are the
hallmark sequences of NBDs of ABC transporters that
display highly conserved sequences across the evolutionary
scale; however, there are also instances of appearance of
selective divergence within this motif. For example, human
ABC transporters such as TAP [35] and CFTR [36] have
degenerated Signature motifs (Figure 6). In contrast, all the
family members of ABC transporters of fungi, particularly of
PDR subfamily display divergence in their Signature motifs.
Thus, the Signature motif of N-NBD of CaCdr1p is well
conserved but has C-NBD with a degenerated Signature
motif (Figure 6). Our recent analysis revealed that the con-
served and degenerated Signature sequences of the CaCdr1p
are functionally indispensable and cannot be exchanged.
This emphasizes the uncompromised asymmetry that exists
between the NBDs of CaCdr1p and in other yeast ABC
transporters. Similar to other ABC transporters, the well-
conserved serine (S304) and glycine (G306) residues present
in conserved Signature motif of N-NBD are also critical for
the functioning of CaCdr1p. For example, even the sub-
stitution at the equivalent position residues of degenerated
Signature motif of C-NBD with the conserved ones and
vice versa does not support the function of the transporter
[25]. The well-conserved glycine present at fourth position
of Signature motif (LSGGQ) is involved in the ATP catalysis
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Table 1: Substrates and inhibitors of CaCDR1 substrates.
Substrates
Fluconazole, ketoconazole, voriconazole, Itraconazole, miconazole, lipids, steroids, R6G,
cycloheximide, rhodamine 123, cerulenin, trifluoperazine, nigericin, tamoxifen, verapamil,
cycloheximide, propanil, diuron, linuron, disulfiram, anisomycin, doxorubicin, 4-nitroquinoline
–N-oxide, benomyl, yohimbine HCl, quinidine, etoposide, chlorobromuron, vinblastine,
tamoxifen, gefitinib, fluphenazine, topotecan, daunorubicin, DM-11, AT-12 niguldipine,
dexamethasone, berberine, terbinafine, tritylmazole
[7, 53]
Inhibitors/modulators Milbemycins, enniatin, FK506, FK520, unnarmicins, curcumin, disulfiram [54–57]
[25, 30, 36–39]. Biochemical analysis revealed that a small
change at this position (G→A) results in steric hindrance
between methyl group of alanine and γ-phosphate of ATP.
If this glycine is exchanged with bulky, charged aspartate
or glutamate, it leads to a complete loss of ATPase and
protein activity [25, 40, 41]. The critical nature of serine
and glycine in WT-CaCdr1p can also be compared with
similar residue of those proteins whose crystal structures
are known. The existing structural information suggests that
the Signature motifs of ABC proteins; Rad50 of Pyrococcus
furiosus, MJ1096 of Methanocaldococcus jannaschii, GlcV
of Sulfolobus solfataricus, Sav1866 of Staphylococcus aureus,
mouse CFTR, HlyB, and MalK of E.coli, are involved in the
head to tail ATPase site formation with the Walker A and
Walker Bmotifs of the opposite NBDs, sandwiched with ATP
molecules wherein the Signature motif is a “sensor” for an
ATP γ-phosphate in the opposing domain [24, 42–49]. Based
on the conserved nature of these motifs, it is reasonable to
speculate that in CaCdr1p, the conserved S304 and G306
of NBD1 probably fall within close proximity of the ATP
binding site. In addition, divergent residues present in C-
NBD Signature region are also equally important and may
be part of the ATPase site as well. However, it still requires
experimental validation.
Additionally, it is shown that in addition to highly
conserved and critical S304 and G306 residues, the equiposi-
tional residues N1002 and E1004 of degenerated Signature
motif of C-NBD of WT-CaCdr1p have also evolved to
be functionally essential. Notably, pairs of residue like
V303, G305 of N-NBD and L1001, V1003, Q1005 of C-
NBD Signature motif though part of otherwise conserved
Signature sequences has apparently no functional relevance.
These residues when replaced with either alanines or with
its equipositional substitutes continued to show phenotypes
similar to cells expressing WT-CaCdr1p.
Functional nonequivalence in the NBDs of ABC proteins
of yeast is the result of variations in the conserved motifs
(Walker A, Walker B, H-loop and Signature motif). These
variations in N-NBD may have evolved in response to
degenerated Signature motif of C-NBD. Thus, in CaCdr1p,
both canonical and noncanonical ATP binding sites are
formed similar to TAP and CFTR proteins. Recently, Ernst
et al. hypothesized that in Pdr5p of S. cerevisiae, one
ATP molecule catalyzed at the canonical active site may
be sufficient to reset the TMDs whereas the second non-
canonical site (regulatory site) may be engaged to serve
as platform for keeping domains in dimeric form (inward
facing) [49, 50].
6. CaCDR1 Extrudes Structurally
Unrelated Substrates
The range of CaCdr1p substrates varies enormously and
includes structurally unrelated compounds such as azoles,
lipids, and steroids (Table 1). This promiscuity towards
substrates is a characteristic feature of most ABC-type
drug transporters and, hence, makes their functionality all
the more complex to understand. Expectedly, predicting
the residues involved in substrate binding without high-
resolution structural data is a challenge. Yet, using a
combination of biochemical assays along with site-directed
mutagenesis, it has been possible to partially dissect the
substrate binding pockets of CaCdr1p wherein role of some
of the TMS amino acids in drug extrusion is becoming
apparent [17, 18, 21].
7. Nature of Substrate Binding
Experiments with purified CaCdr1p have conclusively shown
that ATP binding to CaCdr1p is not a prerequisite for drug
binding and both the mechanisms of drug and ATP binding
result in specific conformational changes which take place
independent of each other [51]. A direct link between the
ability of CaCdr1p to translocate fluorescent glycerophos-
pholipids and efflux drugs has also been demonstrated [51].
Considering chemically diverse substrates which are expelled
by CaCdr1p, the exact number of residues involved in drug
binding and transport is far from understood.
As mentioned earlier, the CaCdr1p was overexpressed as
a GFP-tagged fusion protein in a heterologous hyperexpres-
sion system and was characterized for drugs and nucleotide
binding [52]. Iodoarylazido prazosin (IAAP, a photoaffinity
analogue of P-gp substrate, prazosine) and azidopine (a
dihydropyridine photoaffinity analogue of P-gp modulator,
verapamil) were shown specifically to bind with CaCDR1-
GFP. Interestingly, IAAP binding with CaCdr1p-GFP was
competed out by molar excess of nystatin while azidopine
binding could only be competed out by miconazole, thus,
highlighting the possibility of different drug binding sites
for the two analogues [52]. Gauthier and coworkers [52]
have also shown that membranes prepared form CaCdr1p
and CaCdr2p expressing cells are capable of binding the
photoaffinity analogue of rhodamine 123 (125I) iodoaryl
azido-rhodamine 123 (IAARh123) and that both N-terminal
and C-terminal halves of CaCdr2p contribute to rhodamine
binding [52].
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Figure 7: Cartoon of CaCDR1 protein depicting the location and phenotype of the mutated amino acids. Residues important for the
resistance to CYH have been marked in yellow, defective in ATPase function in green, susceptible to FLC and CYH in blue, susceptible to
FLC and defective in R6G efflux in grey, susceptible to CYH and FLC and defective ATPase function in pink, defective in efflux and susceptible
to CYH, FLC in purple.
To understand the mechanism of drug transport medi-
ated by CaCdr1p, a battery of its mutant variants that
drastically affect various stages of drug extrusion have been
generated (Figure 7). Amino acids of two of the twelve
TMSs of CaCdr1p were subjected to alanine scanning
wherein all the residues were replaced with alanines. The
alanine scanning of TMS 11 of CaCdr1p showed that at
least seven residues which were critical for determining
substrate specificity and drug transport were clustered on
the hydrophilic face of the α helical projection of TMS11
[18]. In contrast, alanine scanning of TMS 5 highlighted
the importance of all 21 residues in drug transport and
substrate specificity [17]. Based on the drug susceptibility
pattern, the mutant variants of the TMS 5 could be grouped
into two categories. The mutants belonging to first category
exhibited sensitivity to all the tested drugs while the mutants
placed in the other category showed intermediate level of
resistance. While the ATPase activity and drug binding
were largely unaffected, rhodamine 6G (R6G) and [3H]
fluconazole (FLC) efflux was abrogated in all the mutant
variants. Based on the competition experiments with the
molar excess of substrates during R6G efflux, we could
identify residues which may be specific for interactions with
miconazole (MCZ), itraconazole (ITR), and ketoconazole
(KTC) and those which were common to all the three azoles.
Notably, FLC which is also a substrate of CaCdr1p did not
compete with R6G efflux; hence implying that CaCdr1p
has independent binding sites for this azole. All the mutant
variants display uncoupling between ATPase activity and
drug transport, and thus TMS 5 of CaCdr1p not only appears
to impart substrate specificity but probably also acts as a
communication helix. What constitutes the substrate/drug
binding pocket and how TMS 5 interacts with other helices
of CaCdr1p are some of the issues that remain to be resolved
(Figure 8).
Together, studies so far suggest that the drug binding
sites in CaCdr1p are scattered throughout the protein and
probably more than one residue of different helices are
involved in binding and extrusion of drugs. However, there
is still insufficient information available to predict where
exactly the most common antifungals, such as azoles bind
and how they are extruded. However, such studies should
pave the way for future investigations related to the dynamics
of substrate selection and may improve our approach in the
design of new inhibitors/modulators of drug transporter for
clinical applications.
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Figure 8: Helical wheel projection of TMS 5 and TMS11 of CaCdr1p. Helical wheel projection of the protein sequence was constructed by the
EMBOSS PEPWHEEL program. This displays the sequence in a helical representation as if looking down the axis of the helix. The hydrophilic
residues as circles, hydrophobic residues as diamonds. Hydrophobicity is color coded as well: the most hydrophobic residue is green, and
the amount of green is decreasing proportionally to the hydrophobicity, with zero hydrophobicity coded as yellow. Hydrophilic residues are
coded red with pure red being the most hydrophilic residue, and the amount of red decreasing proportionally to the hydrophilicity. The
mutations that affected drug resistance are circled blue.
8. Concluding Remarks
The drug transporters belonging to either ABC or MFS
superfamily of proteins are the main contributors of azole
resistance in pathogenic C. albicans. In this regard, CaCdr1p,
a major ABCmultidrug transporter, has been widely studied.
CaCdr1p like its sister fungal homologues is unique in terms
of variant sequences present in otherwise conserved domains
in NBDs. It is established that each unique substitution in
CaCdr1p and by extension of other fungal ABC transporters
have dedicated role in ATP binding and hydrolysis and,
thus, are essential for drug efflux. Why fungal transporters
alone have evolved and retained these divergent domain
based amino acid substitution is not understood. But these
unique residues also provide an opportunity to develop novel
modulators or inhibitors of these efflux pump proteins.
Abbreviations
ABC: ATP binding cassette
MFS: Major facilitator superfamily
IAAP: Iodoarylazido prazosin
NBD: Nucleotide-binding domain
TMSs: Trans membrane segments
TMDs: Trans membrane domains
CDR: Candida drug resistance protein
GFP: Green fluorescence protein.
Acknowledgments
Work cited in this paper from R. Prasad laboratory
is supported in part by Grants from the Department
of Biotechnology, India (BT/PR3825/MED/14/488(a)/2003)
and (BT/PR4862/BRB/10/360/2004), European Commis-
sion, Brussels (QLK-CT-2001-02377), DST-DAAD Grant
(INT/DAAD/p-79/2003), and the Council of Scientific and
Industrial research (CSIR) (37(1132)/03/EMR-II).
References
[1] H. Vanden Bossche, F. Dromer, I. Improvisi, M. Lozano-Chiu,
J. H. Rex, and D. Sanglard, “Antifungal drug resistance in
pathogenic fungi,” Medical Mycology, vol. 36, no. 1, pp. 119–
128, 1998.
[2] M. A. Ghannoum and L. B. Rice, “Antifungal agents: mode
of action, mechanisms of resistance, and correlation of these
mechanisms with bacterial resistance,” Clinical Microbiology
Reviews, vol. 12, no. 4, pp. 501–517, 1999.
[3] T. C. White, K. A. Marr, and R. A. Bowden, “Clinical, cellular,
and molecular factors that contribute to antifungal drug
resistance,” Clinical Microbiology Reviews, vol. 11, no. 2, pp.
382–402, 1998.
[4] H. V. Bossche, P. Marichal, and F. C. Odds, “Molecular mecha-
nisms of drug resistance in fungi,” Trends in Microbiology, vol.
2, no. 10, pp. 393–400, 1994.
Journal of Amino Acids 11
[5] F. C. Odds, Candida and Candidosis: A Review and Bibliogra-
phy, Ballie`re Tindall, London, UK, 1988.
[6] R. Prasad and K. Kapoor, “Multidrug resistance in yeast
Candida,” International Review of Cytology, vol. 242, pp. 215–
248, 2004.
[7] R. Prasad, P. Snehlata, and S. Krishnamurthy, “Drug resistance
mechanisms of human pathogenic fungi,” in Fungal Pathogen-
esis: Principles and Clinical Applications, R. A. Calderone and
R. L. Cihlar, Eds., vol. 14, pp. 601–631, Marcel Dekker, New
York, NY, USA, 2002.
[8] S. L. Kelly, D. C. Lamb, L. Juergen, H. Einsele, and D. E.
Kelly, “The G464S amino acid substitution inCandida albicans
sterol 14α-demethylase causes fluconazole resistance in the
clinic through reduced affinity,” Biochemical and Biophysical
Research Communications, vol. 262, no. 1, pp. 174–179, 1999.
[9] D. C. Lamb, D. E. Kelly, T. C. White, and S. L. Kelly, “The
R467K amino acid substitution inCandida albicans sterol 14α-
demethylase causes drug resistance through reduced affinity,”
Antimicrobial Agents and Chemotherapy, vol. 44, no. 1, pp. 63–
67, 2000.
[10] J. Morschha¨user, “The genetic basis of fluconazole resistance
development in Candida albicans,” Biochimica et Biophysica
Acta, vol. 1587, no. 2-3, pp. 240–248, 2002.
[11] C. F. Higgins, “ABC transporters: physiology, structure and
mechanism—an overview,” Research in Microbiology, vol. 152,
no. 3-4, pp. 205–210, 2001.
[12] C. F. Higgins and K. J. Linton, “The ATP switchmodel for ABC
transporters,” Nature Structural and Molecular Biology, vol. 11,
no. 10, pp. 918–926, 2004.
[13] R. Prasad, P. D. Worgifosse, A. Goffeau, and E. Balzi,
“Molecular cloning and characterisation of a novel gene of
Candida albicans, CDR1, conferring multiple resistance to
drugs and antifungals,” Current Genetics, vol. 27, pp. 320–329,
1995.
[14] D. Sanglard, F. Ischer, M. Monod, and J. Bille, “Cloning
of Candida albicans genes conferring resistance to azole
antifungal agents: characterization of CDR2, a new multidrug
ABC transporter gene,” Microbiology, vol. 143, no. 2, pp. 405–
416, 1997.
[15] R. Franz, S. Michel, and J. Morschha¨user, “A fourth gene from
the Candida albicans CDR family of ABC transporters,” Gene,
vol. 220, no. 1-2, pp. 91–98, 1998.
[16] S. Krishnamurthy, U. Chatterjee, V. Gupta et al., “Deletion of
transmembrane domain 12 of CDR1, a multidrug transporter
from Candida albicans, leads to altered drug specificity:
expression of a yeast multidrug transporter in baculovirus
expression system,” Yeast, vol. 14, no. 6, pp. 535–550, 1998.
[17] N. Puri, M. Gaur, M. Sharma, S. Shukla, S. V. Ambudkar, and
R. Prasad, “The amino acid residues of transmembrane helix 5
of multidrug resistance protein CaCdr1p of Candida albicans
are involved in substrate specificity and drug transport,”
Biochimica et Biophysica Acta, vol. 1788, no. 9, pp. 1752–1761,
2009.
[18] P. Saini, T. Prasad, N. A. Gaur et al., “Alanine scanning
of transmembrane helix 11 of Cdr1p ABC antifungal efflux
pump of Candida albicans: identification of amino acid
residues critical for drug efflux,” Journal of Antimicrobial
Chemotherapy, vol. 56, no. 1, pp. 77–86, 2005.
[19] K. Nakamura, M. Niimi, K. Niimi et al., “Functional expres-
sion of Candida albicans drug efflux pump Cdr1p in a Saccha-
romyces cerevisiae strain deficient in membrane transporters,”
Antimicrobial Agents and Chemotherapy, vol. 45, no. 12, pp.
3366–3374, 2001.
[20] A. Decottignies, A. M. Grant, J. W. Nichols, H. De Wet, D. B.
McIntosh, and A. Goffeau, “ATPase and multidrug transport
activities of the overexpressed yeast ABC protein Yor1p,”
Journal of Biological Chemistry, vol. 273, no. 20, pp. 12612–
12622, 1998.
[21] S. Shukla, P. Saini, S. Smriti, S. Jha, S. V. Ambudkar, and R.
Prasad, “Functional characterization of Candida albicans ABC
transporter Cdr1p,” Eukaryotic Cell, vol. 2, no. 6, pp. 1361–
1375, 2003.
[22] R. Pasrija, D. Banerjee, and R. Prasad, “Structure and
function analysis of CaMdr1p, a major facilitator superfamily
antifungal efflux transporter protein of Candida albicans:
identification of amino acid residues critical for drug/H+
transport,” Eukaryotic Cell, vol. 6, no. 3, pp. 443–453, 2007.
[23] J. E. Walker, M. Saraste, M. J. Runswick, and N. J. Gay,
“Distantly related sequences in the alpha- and beta-subunits
of ATP synthase, myosin, kinases and other ATP-requiring
enzymes and a common nucleotide binding fold,” EMBO
Journal, vol. 1, no. 8, pp. 945–951, 1982.
[24] E. Schneider and S. Hunke, “ATP-binding-cassette (ABC)
transport systems: functional and structural aspects of
the ATP-hydrolyzing subunits/domains,” FEMS Microbiology
Reviews, vol. 22, no. 1, pp. 1–20, 1998.
[25] A. Kumar, S. Shukla, A. Mandal, S. Shukla, S. V. Ambudkar,
and R. Prasad, “Divergent signature motifs of nucleotide
binding domains of ABC multidrug transporter, CaCdr1p of
pathogenic Candida albicans, are functionally asymmetric and
noninterchangeable,” Biochimica et Biophysica Acta, vol. 1798,
no. 9, pp. 1757–1766, 2010.
[26] S. Jha, N. Karnani, S. K. Dhar et al., “Purification and
characterization of the N-terminal nucleotide binding domain
of an ABC drug transporter of Candida albicans: uncommon
cysteine 193 of walker A is critical for ATP hydrolysis,”
Biochemistry, vol. 42, no. 36, pp. 10822–10832, 2003.
[27] P. Saini, N. A. Gaur, and R. Prasad, “Chimeras of the ABC
drug transporter Cdr1p reveal functional indispensability of
transmembrane domains and nucleotide-binding domains,
but transmembrane segment 12 is replaceable with the cor-
responding homologous region of the non-drug transporter
Cdr3p,” Microbiology, vol. 152, no. 5, pp. 1559–1573, 2006.
[28] C. A. Hrycyna, M. Ramachandra, U. A. Germann, P. W.
Cheng, I. Pastan, and M. M. Gottesman, “Both ATP sites
of human P-glycoprotein are essential but not symmetric,”
Biochemistry, vol. 38, no. 42, pp. 13887–13899, 1999.
[29] I. L. Urbatsch, B. Sankaran, S. Bhagat, and A. E. Senior,
“Both P-glycoprotein nucleotide-binding sites are catalytically
active,” Journal of Biological Chemistry, vol. 270, no. 45, pp.
26956–26961, 1995.
[30] G. Szaka´cs, C. O¨zvegy, E. Bakos, B. Sarkadi, and A. Va´radi,
“Role of glycine-534 and glycine-1179 of human multidrug
resistance protein (MDR1) in drug-mediated control of ATP
hydrolysis,” Biochemical Journal, vol. 356, no. 1, pp. 71–75,
2001.
[31] I. L. Urbatsch, K. Gimi, S. Wilke-Mounts, and A. E. Senior,
“Investigation of the role of glutamine-471 and glutamine-
1114 in the two catalytic sites of P-glycoprotein,” Biochemistry,
vol. 39, no. 39, pp. 11921–11927, 2000.
[32] Z. E. Sauna, M. Mu¨ller, X. H. Peng, and S. V. Ambudkar,
“Importance of the conserved walker B glutamate residues,
556 and 1201, for the completion of the catalytic cycle of ATP
hydrolysis by human P-glycoprotein (ABCB1),” Biochemistry,
vol. 41, no. 47, pp. 13989–14000, 2002.
12 Journal of Amino Acids
[33] M. Azzaria, E. Schurr, and P. Gros, “Discrete mutations
introduced in the predicted nucleotide-binding sites of the
mdr1 gene abolish its ability to confer multidrug resistance,”
Molecular and Cellular Biology, vol. 9, no. 12, pp. 5289–5297,
1989.
[34] V. Rai, S. Shukla, S. Jha, S. S. Komath, and R. Prasad,
“Functional characterization of N-terminal nucleotide bind-
ing domain (NBD-1) of a major ABC drug transporter Cdr1p
of Candida albicans: uncommon but conserved Trp326 of
walker B is important for ATP binding,” Biochemistry, vol. 44,
no. 17, pp. 6650–6661, 2005.
[35] E. Procko, I. Ferrin-O’Connell, S. L. Ng, and R. Gaudet,
“Distinct structural and functional properties of the ATPase
sites in an asymmetric ABC transporter,” Molecular Cell, vol.
24, no. 1, pp. 51–62, 2006.
[36] P. Melin, V. Thoreau, C. Norez, F. Bilan, A. Kitzis, and F. Becq,
“The cystic fibrosis mutation G1349D within the signature
motif LSHGH of NBD2 abolishes the activation of CFTR
chloride channels by genistein,” Biochemical Pharmacology,
vol. 67, no. 12, pp. 2187–2196, 2004.
[37] M. Chen, R. Abele, and R. Tampe´, “Functional non-
equivalence of ATP-binding cassette signature motifs in the
transporter associated with antigen processing (TAP),” Journal
of Biological Chemistry, vol. 279, no. 44, pp. 46073–46081,
2004.
[38] B. L. Browne, V. McClendon, and D. M. Bedwell, “Mutations
within the first LSGGQmotif of Ste6p cause defects in a-factor
transport and mating in Saccharomyces cerevisiae,” Journal of
Bacteriology, vol. 178, no. 6, pp. 1712–1719, 1996.
[39] Z. Szentpe´tery, A. Kern, K. Liliom, B. Sarkadi, A. Va´radi, and
E. Bakos, “The role of the conserved glycines of ATP-binding
cassette signature motifs of MRP1 in the communication
between the substrate-binding site and the catalytic centers,”
Journal of Biological Chemistry, vol. 279, no. 40, pp. 41670–
41678, 2004.
[40] O. Ramaen, C. Sizun, O. Pamlard, E. Jacquet, and J. Y.
Lallemand, “Attempts to characterize the NBD heterodimer
of MRP1: transient complex formation involves Gly771 of the
ABC signature sequence but does not enhance the intrinsic
ATPase activity,” Biochemical Journal, vol. 391, no. 3, pp. 481–
490, 2005.
[41] G. Schmees, A. Stein, S. Hunke, H. Landmesser, and E.
Schneider, “Functional consequences of mutations in the
conserved ‘signature sequence’ of the ATP-binding-cassette
protein MalK,” European Journal of Biochemistry, vol. 266, no.
2, pp. 420–430, 1999.
[42] K. P. Hopfner, A. Karcher, D. S. Shin et al., “Structural biology
of Rad50 ATPase: ATP-driven conformational control in DNA
double-strand break repair and the ABC-ATPase superfamily,”
Cell, vol. 101, no. 7, pp. 789–800, 2000.
[43] P. C. Smith, N. Karpowich, L. Millen et al., “ATP binding to
the motor domain from an ABC transporter drives formation
of a nucleotide sandwich dimer,” Molecular Cell, vol. 10, no. 1,
pp. 139–149, 2002.
[44] G. Verdon, S. V. Albers, N. VanOosterwijk, B.W. Dijkstra, A. J.
M. Driessen, and A. M. W. H. Thunnissen, “Formation of the
productive ATP-Mg2+-bound dimer of GlcV, an ABC-ATPase
from Sulfolobus solfataricus,” Journal of Molecular Biology, vol.
334, no. 2, pp. 255–267, 2003.
[45] R. J. P. Dawson and K. P. Locher, “Structure of a bacterial
multidrug ABC transporter,” Nature, vol. 443, no. 7108, pp.
180–185, 2006.
[46] J. Zaitseva, C. Oswald, T. Jumpertz et al., “A structural analysis
of asymmetry required for catalytic activity of an ABC-ATPase
domain dimer,” EMBO Journal, vol. 25, no. 14, pp. 3432–3443,
2006.
[47] M. L. Oldham, D. Khare, F. A. Quiocho, A. L. Davidson, and
J. Chen, “Crystal structure of a catalytic intermediate of the
maltose transporter,” Nature, vol. 450, no. 7169, pp. 515–521,
2007.
[48] H. A. Lewis, S. G. Buchanan, S. K. Burley et al., “Structure of
nucleotide-binding domain 1 of the cystic fibrosis transmem-
brane conductance regulator,” EMBO Journal, vol. 23, no. 2,
pp. 282–293, 2004.
[49] R. Ernst, P. Kueppers, C. M. Klein, T. Schwarzmueller, K.
Kuchler, and L. Schmitt, “A mutation of the H-loop selectively
affects rhodamine transport by the yeast multidrug ABC
transporter Pdr5,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 105, no. 13, pp.
5069–5074, 2008.
[50] R. Ernst, P. Kueppers, J. Stindt, K. Kuchler, and L. Schmitt,
“Multidrug efflux pumps: substrate selection in ATP-binding
cassette multidrug efflux pumps-first come, first served?”
FEBS Journal, vol. 277, no. 3, pp. 540–549, 2010.
[51] S. Shukla, V. Rai, D. Banerjee, and R. Prasad, “Characterization
of Cdr1p, a major multidrug efflux protein of Candida
albicans: purified protein is amenable to intrinsic fluorescence
analysis,” Biochemistry, vol. 45, no. 7, pp. 2425–2435, 2006.
[52] C. Gauthier, S. Weber, A. M. Alarco et al., “Functional simi-
larities and differences between Candida albicans Cdr1p and
Cdr2p transporters,” Antimicrobial Agents and Chemotherapy,
vol. 47, no. 5, pp. 1543–1554, 2003.
[53] N. Puri, O. Prakash, R. Manoharlal, M. Sharma, I. Ghosh,
and R. Prasad, “Analysis of physico-chemical properties
of substrates of ABC and MFS multidrug transporters of
pathogenic Candida albicans,” European Journal of Medicinal
Chemistry, vol. 45, no. 11, pp. 4813–4826, 2010.
[54] M. Sharma, R. Manoharlal, S. Shukla et al., “Curcumin mod-
ulates efflux mediated by yeast ABC multidrug transporters
and is synergistic with antifungals,” Antimicrobial Agents and
Chemotherapy, vol. 53, no. 8, pp. 3256–3265, 2009.
[55] A. R. Holmes, Y. H. Lin, K. Niimi et al., “ABC transporter
Cdr1p contributes more than Cdr2p does to fluconazole efflux
in fluconazole-resistant Candida albicans clinical isolates,”
Antimicrobial Agents and Chemotherapy, vol. 52, no. 11, pp.
3851–3862, 2008.
[56] K. Tanabe, E. Lamping, K. Adachi et al., “Inhibition of fungal
ABC transporters by unnarmicin A and unnarmicin C, novel
cyclic peptides from marine bacterium,” Biochemical and
Biophysical Research Communications, vol. 364, no. 4, pp. 990–
995, 2007.
[57] S. Shukla, Z. E. Sauna, R. Prasad, and S. V. Ambudkar,
“Disulfiram is a potent modulator of multidrug transporter
Cdr1p of Candida albicans,” Biochemical and Biophysical
Research Communications, vol. 322, no. 2, pp. 520–525, 2004.
